Giarc, our drug pipeline is very valuable and of great interest amongst big pharma, pursuing neurological drugs. Let's imagine ACADIA wins the ROW for Trof, will we be able to use NNZ2591 for Retts? Do we want to pursue that option?
What if a third party wins ROW and then buys NEU out, will this allow NNZ 2591 to compete directly with ACADIA for Retts? So many fascinating scenarios for us to juggle. NEU is ripe for big pharma to acquire and push all 4 current ph2 trials to approval stages.
Exciting times ahead, but first let's get FDA approval.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)